|
 
|
ORDERING RELENZA — HOW TO ORDER RELENZA
Guideline 1: Employee Coverage
In order for your organization to have an adequate number of antiviral treatments, first determine which individuals qualify for coverage. It is essential that your management team determine the course of action should a pandemic occur.
- If employee protection is your objective, plan on covering your entire organization, plus families, and vital contractors and suppliers with whom your organization has personal contact
- If continuation of organization’s production and service is your objective, plan on covering only those essential employees with roles crucial to business continuity
Determine if your organization will cover:
- Entire organization
- Senior employees
- Essential employees to business continuity
- Public representative employees
Then consider which, if any, outside stakeholders may qualify for coverage and determine necessary quantities:
- Employee’s family
- Contractors
- Vital suppliers
- Community affiliates
- Employer retirees
Determine total number of people to cover to move on to Guideline 2.
Note: RELENZA is a prescription medicine. Each employee will need a prescription before receiving RELENZA. It is important to consider a patient’s medical history to determine if RELENZA is appropriate for that individual. Refer to “Is RELENZA appropriate for my employees/organization?” in the RELENZA FAQ section.
Guideline 2:
Calculate Number of RELENZA ROTADISKs® to Order
Important Safety Information About RELENZA
RELENZA IS NOT RECOMMENDED FOR TREATMENT OR PROPHYLAXIS OF INFLUENZA IN INDIVIDUALS WITH UNDERLYING AIRWAY DISEASE (SUCH AS ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE).
- Serious cases of bronchospasm, including fatalities, have been reported during treatment with RELENZA in patients with and without underlying airway disease. Many of these cases were reported during postmarketing, and causality was difficult to assess
- RELENZA SHOULD BE DISCONTINUED IN ANY PATIENT WHO DEVELOPS BRONCHOSPASM OR DECLINE IN RESPIRATORY FUNCTION; immediate treatment and hospitalization may be required
- Safety and efficacy have not been demonstrated in patients with high-risk underlying medical conditions
- Patients should be instructed in the use of the delivery system. Instructions should include a demonstration whenever possible
- If treatment with RELENZA is considered for a patient with underlying airway disease, the potential risks and benefits should be carefully weighed. If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care including availability of fast-acting bronchodilators
- Common adverse events in treatment and prophylaxis studies with RELENZA were nausea, diarrhea, sinusitis, viral respiratory infections, headaches, nasal signs and symptoms. The incidence of these adverse events was similar in both groups for RELENZA and placebo-treated groups
- Please see complete Prescribing Information for RELENZA
|
|
|
|
|
|
|
|
Sign Up for Updates 